DDInter856 DDInter262
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Cabozantinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Epoprostenol
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Cabozantinib may lead to a major life threatening interaction when taken with Epoprostenol
Cabozantinib may lead to a major life threatening interaction when taken with Troleandomycin
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Cabozantinib may lead to a major life threatening interaction when taken with Flurbiprofen